EPROSARTAN

Eprosartan is a nonpeptide angiotensin II receptor antagonist which ha s a high affinity for the ATI receptor subtype, When administered at d osages of 400 to 800 my/day (once or twice daily) for 13 weeks to pati ents with mild to moderate essential hypertension, eprosartan signific antly reduced blood pressure compared with placebo, Eprosartan was at least as effective as enalapril 10 to 40 mg/day in a dose-titration st udy in patients with severe hypertension, Eprosartan is generally well tolerated; clinical trials have shown the drug to have a tolerability profile similar to that of placebo, As with other angiotensin II rece ptor antagonists, it does not cause cough. Eprosartan is not metabolis ed by the cytochrome P450 system and therefore has a low potential for drug interactions.